Novo Nordisk (NVO) reported mixed earnings for the third quarter of 2024 but beat Wall Street revenue expectations for its blockbuster weight-loss drug, Wegovy. Novo announced an earnings per share ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback